March 6, 2018 / 1:21 PM / 5 months ago

BRIEF-Allena Pharmaceuticals Initiates First Phase 3 Trial For ALLN-177 In Patients With Enteric Hyperoxaluria

March 6 (Reuters) - Allena Pharmaceuticals Inc:

* ALLENA PHARMACEUTICALS INITIATES FIRST PHASE 3 TRIAL FOR ALLN-177 IN PATIENTS WITH ENTERIC HYPEROXALURIA

* ALLENA PHARMACEUTICALS INC - ‍TOPLINE DATA FROM PHASE 3 TRIAL FOR ALLN-177 EXPECTED IN SECOND HALF OF 2019​

* ALLENA PHARMACEUTICALS INC - ‍EXPECTS TO INITIATE URIROX-2 IN SECOND HALF OF 2018, CONSISTENT WITH PRIOR GUIDANCE​

* ALLENA - ‍INITIATION OF URIROX-1 TRIAL FOLLOWS MULTIPLE INTERACTIONS WITH FDA AFTER WHICH FDA CONFIRMED IT HAD NO COMMENTS ON PROTOCOL​

* ALLENA PHARMACEUTICALS INC - ‍CONTINUES TO ENGAGE WITH FDA TO FINALIZE DESIGN OF URIROX-2​

* ALLENA - ENGAGING FDA TO DISCUSS PURSUING ACCELERATED APPROVAL PATHWAY FOR PLANNED BLA SUBMISSION FOR ALLN-177 IN PATIENTS WITH ENTERIC HYPEROXALURIA​

* ALLENA - ‍BELIEVES PHASE 3 PROGRAM, IF SUCCESSFUL, COULD BE ELIGIBLE FOR MAA VIA CONDITIONAL APPROVAL PATHWAY​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below